As the costs of biologic drugs increase, biosimilars have emerged as an appealing option for controlling costs and expanding access to treatment. While the uptake of biosimilars in the USA started off slowly, it has since gained a rapid pace.  In the first of a multi-part biosimilar series, this episode will explore the evolving biosimilar landscape, including the opportunities and barriers for uptake, as well as the future outlook for biosimilars in the USA. Topics covered include:  Current biosimilar landscape and key players Top barriers and incentives to biosimilar uptake in the USA